nevro - Search News

Nevro, Neutral and Piper Sandler

Piper Sandler raises Nevro stock to Neutral, cuts target to $5.85

Piper Sandler analyst Adam Maeder upgraded shares of Nevro Corp (NYSE:NVRO), a medical device company with a market capitalization of $214 million, to Neutral from Underweight and adjusted the price target to $5.

Business Insider · 1h

Nevro price target raised to $5.85 from $5 at Baird

Baird raised the firm’s price target on Nevro (NVRO) to $5.85 from $5 and keeps a Neutral rating on the shares. The firm noted its acquisition

TipRanks on MSN · 12h

Nevro upgraded to Neutral from Underweight at Piper Sandler

Piper Sandler analyst Adam Maeder upgraded Nevro (NVRO) to Neutral from Underweight with a price target of $5.85, down from $6, after the company

Globus, Nevro

YAHOO!Finance · 19h

Globus Medical to Acquire Nevro in $250 Million Deal to Expand Chronic Pain Treatment Portfolio

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales after the closing of the purchase, with non-GAAP earnings per share ranging from $3.10 to $3.40.

MassDevice · 23h

Globus Medical to acquire Nevro for $250M

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

Seeking Alpha on MSN · 22h

Globus Medical to buy Nevro in $250M all-cash deal

Globus Medical (NYSE:GMED) said it has agreed to buy Nevro (NVRO) through an all-cash deal with an equity value of around $250M. Under the deal, Globus Medical (NYSE:GMED) will buy all of Nevro's (NVRO) stock for $5.

Zacks.com on MSN4h

Nevro (NVRO) Soars 13.9%: Is Further Upside Left in the Stock?

Nevro (NVRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

medtechdive16h

Globus to buy Nevro for $250M

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

20h

Globus Medical to buy California life sciences firm for $250M

Montgomery County's Globus Medical has agreed to acquire a California life sciences company focused on treating chronic pain ...

TMCnet22h

Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders

Ademi & Fruchter LLP is investigating Nevro (NYSE: NVRO) for possible breaches of fiduciary duty and other violations of law in its transaction with Globus Medical.

Nasdaq14d

Here's Why you Should Add Nevro Stock to Your Portfolio Now

Nevro NVRO is well-poised for growth in the coming quarters, courtesy of its business expansion plans and restructuring activities. The optimism, led by a decent preliminary full-year 2024 ...

Nevro price target raised to $5.85 from $4 at Canaccord

Canaccord raised the firm’s price target on Nevro (NVRO) to $5.85 from $4 and keeps a Hold rating on the shares. The firm noted Globus Medical ...

TMCnet21h

NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Nevro Corp. (NYSE: NVRO) to Globus Medical for $5.85 per share is fair to Nevro shareholders.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results

Nevro, Neutral and Piper Sandler

Globus, Nevro

Related topics